Reported adverse effects in children treated with MTX
| Reference | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 6 | 7 | 31 | 32 | 33 | 34 | 1 | 35 | Total | |
| Modified from Singsen et al.36 | |||||||||
| *ND, not determined. | |||||||||
| Patients | 19 | 23 | 12 | 19 | 30 | 62 | 86 | 26 | 277 |
| Therapy duration | |||||||||
| Mean (months) | 10.5 | 19.2 | 6 | 18.5 | 27 | 6 | |||
| Range (months) | 4–10 | 6–52 | 6 | 8–39 | 6–30 | 19–65 | 6–72 | 4–72 | |
| MTX dose | |||||||||
| mg/m2/wk | 4–17 | 8–25 | 5–15 | 5–20 | 5 or 10 | 10–15 | |||
| mg/kg/wk | 0.1–0.6 | 0.4–0.8 | |||||||
| Adverse effects | |||||||||
| Gastrointestinal symptoms | 2 | 0 | 1 | 2 | 6 | 14 | 8 | 0 | 33 (11.91) |
| Peptic ulcer | 0 | 0 | ND | 0 | 0 | 4 | 0 | 1 | 5 (1.80) |
| Stomatitis | 1 | 0 | ND | 1 | 0 | 0 | 2 | 1 | 5 (1.80) |
| Mouth ulcers | 1 | 0 | 1 | 0 | 2 | 0 | 1 | 0 | 4 (1.44) |
| Rashes | 0 | 0 | ND | 0 | ND | 0 | 1 | 0 | 1 (0.36) |
| Alopecia | ND | 0 | ND | 0 | ND | 2 | 0 | 0 | 2 (0.72) |
| Jaundice | 0 | 0 | ND | 0 | ND | ND | 0 | 1 | 1 (0.36) |
| Bacterial infections | 0 | 0 | ND | ND | ND | 4 | 0 | ND | 4 (1.44) |
| Herpes zoster | 1 | 0 | 0 | 0 | 1 | 1 | 0 | ND | 3 (1.08) |
| Mood changes | 0 | ND | 1 | ND | ND | ND | 0 | ND | 1 (0.36) |
| Liver function test elevations | 3 | 10 | 1 | 1 | 3 | 9 | 1 | 4 | 25 (9.03) |
| Haematuria | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 (0.00) |
| Leucopenia | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 (0.36) |
| Anaemia | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 (0.36) |
| Proteinuria | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 (1.08) |